FLT3-ITD MRD dynamics predicted relapse risk and shaped response to gilteritinib maintenance in post-transplant AML.

Precise MRD detected tumor fractions as low as 0.0001% (1 part per million) and showed a clinically meaningful lead time in detecting recurrence compared to imaging.

Measurement of minimal residual disease (MRD) following treatment of blood cancers is recognized as an important tool for disease management, and MRD negativity is increasingly a benchmark in ...

Tracer Biotechnologies, a leader in blood-based molecular diagnostics for cancer, is pleased to announce a strategic partnership with QIAGEN to co-develop and commercialize minimal residual ...

Myriad Genetics, Inc. (NASDAQ:MYGN) is making waves at the 2025 ASCO Annual Meeting, presenting seven new research studies that underscore major advances in molecular diagnostics and precision ...

Adaptive Biotechnologies hired Goldman Sachs to review strategic alternatives. “All options are on the table right now,” said CEO Chad Robins, ...

Strayhon was one of seven individuals who died in Gwinnett County Jail in 2021, ranking it in first place amongst deaths in metro Atlanta jails.